GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (NAS:BOLT) » Definitions » Operating Margin %
中文

Bolt Biotherapeutics (Bolt Biotherapeutics) Operating Margin %

: -946.19% (As of Dec. 2023)
View and export this data going back to 2021. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. Bolt Biotherapeutics's Operating Income for the three months ended in Dec. 2023 was $-19.77 Mil. Bolt Biotherapeutics's Revenue for the three months ended in Dec. 2023 was $2.09 Mil. Therefore, Bolt Biotherapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -946.19%.

The historical rank and industry rank for Bolt Biotherapeutics's Operating Margin % or its related term are showing as below:

BOLT' s Operating Margin % Range Over the Past 10 Years
Min: -21290.91   Med: -7364.13   Max: -967.45
Current: -967.45


BOLT's Operating Margin % is ranked worse than
72.68% of 1025 companies
in the Biotechnology industry
Industry Median: -177.8 vs BOLT: -967.45

Bolt Biotherapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Bolt Biotherapeutics's Operating Income for the three months ended in Dec. 2023 was $-19.77 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-76.20 Mil.


Bolt Biotherapeutics Operating Margin % Historical Data

The historical data trend for Bolt Biotherapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bolt Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial -14,404.19 -21,290.91 -7,364.13 -1,576.56 -967.45

Bolt Biotherapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,491.14 -1,008.49 -1,383.95 -719.26 -946.19

Competitive Comparison

For the Biotechnology subindustry, Bolt Biotherapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bolt Biotherapeutics Operating Margin % Distribution

For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Bolt Biotherapeutics's Operating Margin % falls into.



Bolt Biotherapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Bolt Biotherapeutics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-76.196 / 7.876
=-967.45 %

Bolt Biotherapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-19.766 / 2.089
=-946.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bolt Biotherapeutics  (NAS:BOLT) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Bolt Biotherapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bolt Biotherapeutics (Bolt Biotherapeutics) Business Description

Traded in Other Exchanges
Address
900 Chesapeake Drive, Redwood, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
Executives
William P. Quinn officer: Chief Financial Officer SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Edgar Engleman director 575 HIGH STREET, STE 201, PALO ALTO CA 94301
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Laura Berner director C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Brian O'callaghan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Frank D. Lee director C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Kathleen Laporte director
Miller Richard A Md director PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Mahendra Shah director 2250 HOLCOMBE BLVD, HOUSTON TX 77030
Grant Yonehiro officer: Chief Business Officer C/O MAXYGEN, INC., 515 GALVESTON DRIVE, REDWOOD CITY CA 94063
Randall C Schatzman director, officer: Chief Executive Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
David Dornan officer: Chief Scientific Officer C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Edith A. Perez officer: Chief Medical Officer C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTONE DRIVE, REDWOOD CITY CA 94063

Bolt Biotherapeutics (Bolt Biotherapeutics) Headlines

From GuruFocus